{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T07:14:32Z","timestamp":1791357272920,"version":"4.3.1"},"reference-count":41,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2013,5,20]],"date-time":"2013-05-20T00:00:00Z","timestamp":1369008000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Epilepsia"],"published-print":{"date-parts":[[2013,7]]},"abstract":"Summary<\/jats:title>Purpose<\/jats:title>HLA<\/jats:styled-content>\u2010B*15:02 screening is recommended before starting carbamazepine in H<\/jats:styled-content>an C<\/jats:styled-content>hinese and Southeast Asians because the allele is strongly predictive of S<\/jats:styled-content>tevens\u2010J<\/jats:styled-content>ohnson syndrome (SJS<\/jats:styled-content>)\/toxic epidermal necrolysis (TEN<\/jats:styled-content>) induced by the drug. We examined whether other HLA<\/jats:styled-content>\u2010B<\/jats:styled-content> alleles are also involved and whether the association extends to other antiepileptic drugs (AED<\/jats:styled-content>s).<\/jats:p><\/jats:sec>Methods<\/jats:title>Cases of SJS<\/jats:styled-content>\/TEN<\/jats:styled-content> induced by any AED<\/jats:styled-content>s were recruited and matched (1:5) with AED<\/jats:styled-content>\u2010tolerant controls. Carrier rates of HLA<\/jats:styled-content>\u2010B<\/jats:styled-content> alleles, determined by direct sequencing, were compared between cases and controls. Results were meta\u2010analyzed with previous studies to examine the associations between HLA<\/jats:styled-content>\u2010B<\/jats:styled-content>*15:02 and SJS<\/jats:styled-content>\/TEN<\/jats:styled-content> induced by phenytoin and lamotrigine.<\/jats:p><\/jats:sec>Key Findings<\/jats:title>A total of 55 cases (27 carbamazepine, 15 phenytoin, 6 lamotrigine, 7 other AED<\/jats:styled-content>s) and 275 controls were recruited. In drug\u2010specific analysis, the carrier rate of HLA<\/jats:styled-content>\u2010B<\/jats:styled-content>*15:02 was significantly higher in carbamazepine\u2010SJS<\/jats:styled-content>\/TEN<\/jats:styled-content> cases compared with carbamazepine\u2010tolerant controls (92.3% vs. 11.9%; p\u00a0=\u00a03.51\u00a0\u00d7\u00a010\u221218<\/jats:sup>; odds ratio (OR<\/jats:styled-content>) 89.25; 95% confidence interval (CI<\/jats:styled-content>) 19.25\u2013413.83), and also in phenytoin\u2010SJS<\/jats:styled-content>\/TEN<\/jats:styled-content> cases compared with phenytoin\u2010tolerant controls (46.7% vs. 20.0%; p\u00a0=\u00a00.045; OR<\/jats:styled-content> 3.50; 95% CI<\/jats:styled-content> 1.10\u201311.18). Meta\u2010analyses showed a strong association of HLA<\/jats:styled-content>\u2010B<\/jats:styled-content>*15:02 with phenytoin\u2010SJS\/TEN (p\u00a0<\u00a03\u00a0\u00d7\u00a010\u22124<\/jats:sup>; OR<\/jats:styled-content> 4.26; 95% CI<\/jats:styled-content> 1.93\u20139.39) and, to a lesser extent, lamotrigine\u2010SJS<\/jats:styled-content>\/TEN<\/jats:styled-content> (p\u00a0=\u00a00.03; OR<\/jats:styled-content> 3.59; 95% CI<\/jats:styled-content> 1.15\u201311.22). Compared with drug\u2010tolerant controls, the carrier rates of HLA<\/jats:styled-content>\u2010B<\/jats:styled-content>*40:01 and HLA<\/jats:styled-content>\u2010B<\/jats:styled-content>*58:01 were lower in cases of SJS<\/jats:styled-content>\/TEN<\/jats:styled-content> induced by carbamazepine (p\u00a0=\u00a00.004) and other AED<\/jats:styled-content>s (p\u00a0=\u00a00.009), respectively.<\/jats:p><\/jats:sec>Significance<\/jats:title>SJS<\/jats:styled-content>\/TEN<\/jats:styled-content> induced by carbamazepine and phenytoin is strongly and moderately associated with HLA<\/jats:styled-content>\u2010B<\/jats:styled-content>*15:02 in H<\/jats:styled-content>an C<\/jats:styled-content>hinese, respectively. Possible protective associations with HLA<\/jats:styled-content>\u2010B<\/jats:styled-content>*40:01 and HLA<\/jats:styled-content>\u2010B<\/jats:styled-content>*58:01 warrant further investigation.<\/jats:p><\/jats:sec>","DOI":"10.1111\/epi.12217","type":"journal-article","created":{"date-parts":[[2013,5,20]],"date-time":"2013-05-20T13:10:46Z","timestamp":1369055446000},"page":"1307-1314","source":"Crossref","is-referenced-by-count":160,"title":["HLA<\/scp>\u2010B<\/scp> alleles associated with severe cutaneous reactions to antiepileptic drugs in H<\/scp>an C<\/scp>hinese"],"prefix":"10.1111","volume":"54","author":[{"given":"Ying\u2010Kit","family":"Cheung","sequence":"first","affiliation":[{"name":"Department of Medicine and Therapeutics The Chinese University of Hong Kong Prince of Wales Hospital Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suk\u2010Hang","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Anatomical and Cellular Pathology The Chinese University of Hong Kong Prince of Wales Hospital Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernest J. M.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics The Chinese University of Hong Kong Prince of Wales Hospital Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Su V.","family":"Lo","sequence":"additional","affiliation":[{"name":"Division of Planning & Strategy Hospital Authority Head Office Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret H. L.","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Anatomical and Cellular Pathology The Chinese University of Hong Kong Prince of Wales Hospital Hong Kong China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Kwan","sequence":"additional","affiliation":[{"name":"Department of Medicine and Therapeutics The Chinese University of Hong Kong Prince of Wales Hospital Hong Kong China"},{"name":"Departments of Medicine and Neurology The University of Melbourne Royal Melbourne Hospital Melbourne Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,5,20]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.7.6.813"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2008.04.003"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2010.10.006"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2010.04745.x"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/428486a"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2011.01.005"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0409500102"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.fpc.0000199500.46842.4a"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.2217\/pgs.09.162"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02269.x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature11147"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.2217\/14622416.9.11.1617"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02766.x"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.08.013"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/FPC.0b013e3283117d67"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2012.04.041"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01719.x"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706135"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01022.x"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1013297"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.4103\/0378-6323.57718"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.0001-2815.2004.00234.x"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2010.11.022"},{"key":"e_1_2_7_25_1","unstructured":"Novartis. (2010)Tegretol prescribing information. Available at:http:\/\/www.accessdata.fda.gov\/Drugsatfda_docs\/label\/2011\/016608s100s102 018281s049s050 018927s041s042 020234s031s033lbl.pdf. Accessed December 8 2012."},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddq537"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199411103311906"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02096.x"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2011.00681.x"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-7843.2012.00868.x"},{"key":"e_1_2_7_31_1","first-page":"357","article-title":"Cutaneous drug reactions","volume":"53","author":"Svensson CK","year":"2001","journal-title":"Pharmacol Rev"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2010.02533.x"},{"key":"e_1_2_7_33_1","first-page":"290","article-title":"Frequency of the HLA\u2010B*1502 allele contributing to carbamazepine\u2010induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients","volume":"29","author":"Then SM","year":"2011","journal-title":"Asian Pac J Allergy Immunol"},{"key":"e_1_2_7_34_1","volume-title":"IHWG technical manual genomic analysis of the human MHC: DNA\u2010based typing for HLA alleles and linked polymorphisms","author":"Tilanus MGJ","year":"2002"},{"key":"e_1_2_7_35_1","unstructured":"US Food and Drug Administration. (2008)Phenytoin and fosphenytoin information. Available at:http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/ucm110259.htm. Accessed December 8 2012."},{"key":"e_1_2_7_36_1","unstructured":"US Food and Drug Administration. (2012)Table of pharmacogenomic biomarkers in drug labels. Available at:http:\/\/www.fda.gov\/drugs\/scienceresearch\/researchareas\/pharmacogenetics\/ucm083378.htm. Accessed December 8 2012."},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2011.02.003"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1177\/147323001204000140"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2011.12.990"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2010.08.007"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e31823b478c"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-011-1009-4"}],"container-title":["Epilepsia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fepi.12217","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/epi.12217","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T02:05:57Z","timestamp":1696298757000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/epi.12217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,20]]},"references-count":41,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["10.1111\/epi.12217"],"URL":"https:\/\/doi.org\/10.1111\/epi.12217","archive":["Portico"],"relation":{},"ISSN":["0013-9580","1528-1167"],"issn-type":[{"value":"0013-9580","type":"print"},{"value":"1528-1167","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,20]]}}}